InvestorsHub Logo
Followers 67
Posts 1293
Boards Moderated 0
Alias Born 08/12/2014

Re: None

Friday, 12/09/2022 9:21:50 AM

Friday, December 09, 2022 9:21:50 AM

Post# of 700283
Approvals are in the card, nothing has changed. Even old school Stupp agrees (he doesn't imply he disagree anyway). Anyone who may question like Stupp whether efficacy of DCVax-L for nGBM is derived from biases or some kind of accident, or something else but DCVax-L, just ask this simple question: if the efficacy not from DCVax-L, why the same DCVax-L in the same trial for the same patient population has produced this resounding, hugely positive OS improvement for rGBM patients?

It would be an elementary reasoning, and the conclusion is yes the efficacy seen for nGBM in the trial is indeed from DCVax-L, and it's impossible from anything other that!

Added 30k shares yesterday to my well over 7-figure existing shares after carefully comprehend Stupp's commantary. I don't know how price will be today or on the days ahead, I do know it's vastly undervalued in the long run. Intended to buy more when price is still in such ranges.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News